[artículo] 
inCNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353

Título :	A long-term, open-label study of valbenazine for tardive dyskinesia
Tipo de documento:	texto impreso
Autores:	Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 345 - 353
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo
Resumen:	Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine.
Link:	./index.php?lvl=notice_display&id=28341

[artículo] A long-term, open-label study of valbenazine for tardive dyskinesia [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor . - 2022 . - pp. 345 - 353.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in CNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353

Palabras clave:	Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo
Resumen:	Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine.
Link:	./index.php?lvl=notice_display&id=28341